AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01926444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-1001
Description: GIC-1001 oral tablet, white-coated, to be taken with water
Study NCT01926444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIC-1001
Description: GIC-1001 oral tablet, white-coated, to be taken with water
Study NCT02460068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fotemustine
Description: Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
Study NCT02460068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fotemustine and Ipilimumab
Description: Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
Study NCT02460068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Description: ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
Study NCT03673280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
Study NCT03673280 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
Study NCT00652743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine GSK1562902A
Description: IM administration
Study NCT02804633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Acetaminophen
Description: 1 gram every 6 hours
Study NCT02804633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of normal saline every 6 hours
Study NCT00205153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy TEAM monitoring and counseling
Description: Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
Study NCT04508933 — intervention group
Intervention type: DEVICE
Intervention: Extravascular Lung Water Index
Description: Measurement of the EVLWI
Study NCT04508933 — intervention group
Intervention type: DEVICE
Intervention: Pulmonary Vascular Permeability Index
Description: Measurement of the PVPI
Study NCT00381719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: 3 mg Capsule twice daily for 4 weeks
Study NCT00381719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: 20 mg Capsule twice daily for 4 weeks
Study NCT00381719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: 60 mg Capsule twice daily for 4 weeks
Study NCT00381719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Capsule twice daily for 4 weeks
Study NCT05777668 — intervention group
Intervention type: RADIATION
Intervention: Volumetric modulated radiotherapy
Study NCT00043745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Description: Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
Study NCT00043745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Extract tablets
Description: Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
Study NCT01945996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TExT MED
Description: educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
Study NCT01945996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TExT MED
Description: educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
Study NCT01945996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FANS
Description: supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
Study NCT02628041 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Permanent Iodine-125 seed implant
Description: Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure.
Study NCT02628041 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose-rate Prostate Brachytherapy
Description: High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed.
Study NCT00411385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin interferon alfa-2b
Description: 900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
Study NCT00411385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a
Description: 180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
Study NCT00411385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800mg/day for 24 weeks
Study NCT00411385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 800mg/day for 24 weeks
Study NCT02576795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
Study NCT00592930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: flexibly dosed oral olanzapine 2.5 to 15 mg/day
Study NCT00592930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04563351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local anaesthetic techniques
Description: The patients were anesthetized with two different local anaesthetic techniques.
Study NCT04563351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic techniques
Description: The patients were anesthetized with two different local anaesthetic techniques.
Study NCT00418457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia and opioids
Description: General anesthesia, usually with sevoflurane, and opioid analgesia
Study NCT00418457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional analgesia and propofol
Description: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
Study NCT01631344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily physical activity consultation, Using the Stage of change model
Description: Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
Study NCT01552941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberonics VNS System
Description: Active Implantable Electrical Vagal Nerve Stimulator
Study NCT03460730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax
Description: 23-valent pneumococcal polysaccharide vaccine
Study NCT02349529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention Group
Description: 6 group sessions
Study NCT02349529 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list control
Description: Treatment as usual
Study NCT03600571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medial midpatellar (MMP) portal
Description: injection medial under horizontal patella midline was administrated with the lower limb extension
Study NCT03600571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anteromedial (AM) portal
Description: injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion
Study NCT02381145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG+RSV-supplementation
Description: Teavigo (\~300mg/d) Resveratrol (\~80mg/d)
Study NCT02381145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00751933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Vivotif + Vaccine Dukoral + oats
Description: Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.~One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
Study NCT03413033 — intervention group
Intervention type: OTHER
Intervention: Resonance tube
Description: Participants will phonate into a tube (10cm length 4mm inner diameter) during 5 minutes. They will produce series of the vowel /u/ into the tube. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
Study NCT00751933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Vivotif + Vaccine Dukoral
Description: Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
Study NCT00751933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oats
Description: One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
Study NCT00751933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
Study NCT03334539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HL036 ophthalmic solution
Description: HL036 ophthalmic solution
Study NCT03413033 — intervention group
Intervention type: OTHER
Intervention: Tongue trill
Description: Participants will produce series of a similar /r/ Spanish sound during 5 minutes. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
Study NCT02971293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871 100 µg
Description: The subjects will receive one dose of AZD8871 100 µg single dose DPI.
Study NCT03334539 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vehicle solution
Description: Placebo vehicle solution
Study NCT00967057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given intramuscularly
Study NCT00967057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT03055689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational telephone intervention
Description: Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
Study NCT02971293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871 600 µg
Description: The subjects will receive AZD8871, 600 µg single dose DPI.
Study NCT02971293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive Placebo single dose DPI.
Study NCT01400139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate q24h film-coated tablets
Description: Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
Study NCT00672295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, Paclitaxel, and Carboplatin
Description: Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m\^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn.
Study NCT01150786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium Supplement
Description: The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
Study NCT01150786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patients in this arm took one placebo capsule daily for 12 weeks.
Study NCT02501681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: priming solution during cardiovascular surgery
Study NCT03976505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reading a table format prescription on a touch screen
Description: Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
Study NCT03976505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reading a table format prescription on a touch screen
Description: Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
Study NCT00175071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison of cooking oils
Description: 30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
Study NCT03976505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reading a textual format prescription on a touch screen
Description: Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
Study NCT03976505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reading a textual format prescription on a touch screen
Description: Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
Study NCT03976505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: filling a virtual pillbox displayed on the screen as prescribed in the prescription
Description: filling a virtual pillbox displayed on the screen as prescribed in the prescription
Study NCT02505815 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Study NCT00967057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT00967057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally
Study NCT03055689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education for colonoscopy
Description: Standard education for bowel preparation at the time of colonoscopy scheduling
Study NCT02505815 — intervention group
Intervention type: PROCEDURE
Intervention: Cortisol Level Measurement
Study NCT01460667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
Study NCT01460667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: 0.9% normal saline IV, every 6 hours over 30 hours.
Study NCT02505815 — intervention group
Intervention type: PROCEDURE
Intervention: Neurocognitive Testing
Study NCT04194957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (capecitabine or 5-fluorouracil)
Description: Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.
Study NCT04194957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (capecitabine or 5-fluorouracil)
Description: Patients that are heterozygous carriers of c.1236G>A or c.2846A>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.
Study NCT04194957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (capecitabine or 5-fluorouracil)
Description: Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.
Study NCT06211452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARM A: Active Comparator Drug
Description: Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8, 15, 22; cytarabine 75 mg/m2/d, on days 3-6, 10-13, 17-20, 24-27, 31-34, 38-41; intrathecal cytarabine on days 1, 15, 29, 43; cyclophosphamide 500 mg/m2/d, days 29, 43.
Study NCT06211452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM B: Blocks Therapy Drug
Description: Blocks AI Cytarabine 500 mg/m2 as 24 infusion infusion x 4 d; Idarubicin 7 mg/m2 on days 3 and 5; Intrathecal cytarabine on days 0 and 6.~haM Cytarabine 1 g/m2 every 12 hours for 3 days; Mitoxantrone 10 mg/m2 days 4 and 5; Intrathecal cytarabine days 6 and 15.
Study NCT03391076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray Respiratory Panel
Description: An Multi-PCR method which can detect 20 pathogens in 45 minutes.
Study NCT04355221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency
Description: Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device
Study NCT04355221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency
Description: Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device
Study NCT01937624 — intervention group
Intervention type: DEVICE
Intervention: Diagnostic Ultrasound
Study NCT01937624 — intervention group
Intervention type: RADIATION
Intervention: X-ray imaging
Study NCT02268136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIII 890 CL
Study NCT02268136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04616092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEFINJECT
Description: FEFINJECT injection
Study NCT02451488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 14 days in a dose of 125 µg/m\^2
Study NCT02451488 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: No neo-adjuvant therapy prior to surgical intervention
Study NCT05247983 — intervention group
Intervention type: PROCEDURE
Intervention: Tension-free repair of inguinal hernia with Undissociate Spermatic cord
Description: patient undergoing Tension-free repair of inguinal hernia with Undissociate Spermatic cord
Study NCT01386892 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study